NARA Discovery
Article Details
← Back to Search Results
Journal Article

Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey

Joanna Kuc; Hannes Kettner; Fernando Rosas; David Erritzoe; Eline Haijen; Mendel Kaelen; David Nutt; Robin L. Carhart-Harris
Psychopharmacology · Vol. 239, Issue 5 · pp. 1425-1440 · 2022

Abstract

Rationale. Classic psychedelics are currently being studied as novel treatments for a range of psychiatric disorders. However, research on how psychedelics interact with other psychoactive substances remains scarce. Objectives The current study aimed to explore the subjective effects of psychedelics when used alongside cannabis. Methods Participants ( n = 321) completed a set of online surveys at 2 time points: 7 days before, and 1 day after a planned experience with a serotonergic psychedelic. The collected data included demographics, environmental factors (so-called setting) and five validated questionnaires: Mystical Experience Questionnaire (MEQ), visual subscales of Altered States of Consciousness Questionnaire (ASC-Vis), Challenging Experience Questionnaire (CEQ), Ego Dissolution Inventory (EDI) and Emotional Breakthrough Inventory (EBI). Participants were grouped according to whether they had reported using no cannabis ( n = 195) or low ( n = 53), medium ( n = 45) or high ( n = 28) dose, directly concomitant with the psychedelic. Multivariate analysis of covariance (MANCOVA) and contrasts was used to analyse differences in subjective effects between groups while controlling for potential confounding contextual ‘setting’ variables. Results The simultaneous use of cannabis together with classic serotonergic psychedelics was associated with more intense psychedelic experience across a range of measures: a linear relationship was found between dose and MEQ, ASC-Vis and EDI scores, while a quadratic relationship was found for CEQ scores. No relationship was found between the dose of cannabis and the EBI. Conclusions Results imply a possible interaction between the cannabis and psychedelic on acute subjective experiences; however, design limitations hamper our ability to draw firm inferences on directions of causality and the clinical implications of any such interactions.

Bibliographic Information

JournalPsychopharmacology
PublisherSpringer
Publication Date2022-05-01
Publication Year2022
Volume239
Issue5
Pages1425-1440
Document TypeJournal Article
Print ISSN0033-3158
eISSN1432-2072
DOI10.1007/s00213-021-05999-1

Access Information

NARA Access Coverage1959-01-01~Current
Journal Homepagehttps://www.springer.com/journal/213
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.